Abstract
Background: The Renin Angiotensin System (RAS) is pharmacologically targeted to reduce blood pressure, and patient compliance to oral medications is a clinical issue. The mechanisms of action of angiotensin receptor blockers (ARBs) in reducing blood pressure are not well understood and are purported to be via a reduction of angiotensin II signaling.
Objective: We aimed to develop a transdermal delivery method for ARBs (losartan potassium and valsartan) and to determine if ARBs reveal a vasodilatory effect of the novel RAS peptide, alamandine. In addition, we determined the anti-hypertensive effects of the transdermal delivery patch.
Methods: In vitro and in vivo experiments were performed to develop an appropriate therapeutic system, promising an alternative and more effective therapy in the treatment of hypertension. A variety of penetration enhancers were selected such as isopropyl myristate, propylene glycol, transcutol and dimenthyl sulfoxide to obtain a constant release of drugs through human skin. Small resistance vessels (kidney interlobar arteries) were mounted in organ baths and incubated with an ARB. Vasodilatory curves to alamandine were constructed.
Results: The in vivo studies demonstrate that systemic absorption of valsartan and losartan potassium using the appropriate formulations provide a steady state release and anti-hypertensive effect even after 24 hours of transdermal administration. No apparent skin irritations (erythema, edema) were observed with the tested formulations. We also show that blocking the AT1 receptor of rabbit interlobar arteries in vitro reveals a vasodilatory effect of alamandine.
Conclusion: This study reveals the potential mechanism of AT1 receptor blockade via alamandine, and is an important contribution in developing a favorable, convenient and painless antihypertensive therapy of prolonged duration through transdermal delivery of AT1 blockers.
Keywords: Losartan, valsartan, alamandine, hypertension, skin, skin patch, anti-hypertensive drug delivery, blood pressure.
Graphical Abstract
Current Molecular Pharmacology
Title:Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels
Volume: 11
Author(s): Michaila Michalatou, Maria Eleni Androutsou, Markos Antonopoulos, Demetrios V. Vlahakos, George Agelis, Anthony Zulli, Tawar Qaradakhi, Kathleen Mikkelsen, Vasso Apostolopoulos*John Matsoukas*
Affiliation:
- Institute for Health and Sport, Victoria University, Melbourne, VIC 3030,Australia
- Department of Chemistry, University of Patras, Patras, 26500,Greece
Keywords: Losartan, valsartan, alamandine, hypertension, skin, skin patch, anti-hypertensive drug delivery, blood pressure.
Abstract: Background: The Renin Angiotensin System (RAS) is pharmacologically targeted to reduce blood pressure, and patient compliance to oral medications is a clinical issue. The mechanisms of action of angiotensin receptor blockers (ARBs) in reducing blood pressure are not well understood and are purported to be via a reduction of angiotensin II signaling.
Objective: We aimed to develop a transdermal delivery method for ARBs (losartan potassium and valsartan) and to determine if ARBs reveal a vasodilatory effect of the novel RAS peptide, alamandine. In addition, we determined the anti-hypertensive effects of the transdermal delivery patch.
Methods: In vitro and in vivo experiments were performed to develop an appropriate therapeutic system, promising an alternative and more effective therapy in the treatment of hypertension. A variety of penetration enhancers were selected such as isopropyl myristate, propylene glycol, transcutol and dimenthyl sulfoxide to obtain a constant release of drugs through human skin. Small resistance vessels (kidney interlobar arteries) were mounted in organ baths and incubated with an ARB. Vasodilatory curves to alamandine were constructed.
Results: The in vivo studies demonstrate that systemic absorption of valsartan and losartan potassium using the appropriate formulations provide a steady state release and anti-hypertensive effect even after 24 hours of transdermal administration. No apparent skin irritations (erythema, edema) were observed with the tested formulations. We also show that blocking the AT1 receptor of rabbit interlobar arteries in vitro reveals a vasodilatory effect of alamandine.
Conclusion: This study reveals the potential mechanism of AT1 receptor blockade via alamandine, and is an important contribution in developing a favorable, convenient and painless antihypertensive therapy of prolonged duration through transdermal delivery of AT1 blockers.
Export Options
About this article
Cite this article as:
Michalatou Michaila , Androutsou Eleni Maria , Antonopoulos Markos , Vlahakos V. Demetrios, Agelis George , Zulli Anthony , Qaradakhi Tawar , Mikkelsen Kathleen , Apostolopoulos Vasso *, Matsoukas John *, Transdermal Delivery of AT1 Receptor Antagonists Reduce Blood Pressure and Reveal a Vasodilatory Effect on Kidney Blood Vessels, Current Molecular Pharmacology 2018; 11 (3) . https://dx.doi.org/10.2174/1874467211666180419152036
DOI https://dx.doi.org/10.2174/1874467211666180419152036 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ACE2-Ang-(1-7)-Mas Axis in Brain: A Potential Target for Prevention and Treatment of Ischemic Stroke
Current Neuropharmacology A Case of Heavy Proteinuric Non-IgA Mesangial Proliferative Glomerulonephritis Ameliorated by Chinese Herbal Medicines
Current Traditional Medicine New Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus
Current Medicinal Chemistry Physiological and Pharmacological Regulation of Hepatic 3-Hydroxy-3- Methylglutaryl Coenzyme A Reductase
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents <i>Brassica oleracea</i> var. <i>capitata f. alba</i>: A Review on its Botany, Traditional uses, Phytochemistry and Pharmacological Activities
Mini-Reviews in Medicinal Chemistry Arterial Accelerated Aging in Dialysis Patients: The Clinical Impact of Vascular Calcification
Current Vascular Pharmacology Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Systems Biology of HBOC-Induced Vasoconstriction
Current Drug Discovery Technologies A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Oxidative Stress, Endothelial Function and Angiogenesis Induced by Cell Therapy and Gene Therapy
Current Pharmaceutical Biotechnology Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews The “Neurocentric” Approach to Essential Hypertension: How Reliable is the Paradigm of Hyperkinetic Hypertension? A Focus on the Sympathetic Nervous System Dysregulation in Essential Hypertensive Patients with Elevated Resting Heart Rate
Current Pharmaceutical Design Intra - and Intercellular Calcium Handling in Pulmonary Arterial Hypertension
Medicinal Chemistry Sustained Release of Verapamil Hydrochloride from Sodium Alginate Microcapsules
Current Drug Delivery Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry Cytostatic Properties of Some Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type I Receptor Antagonists
Current Pharmaceutical Design Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Marine Bioactive Peptides in Supplements and Functional Foods - A Commercial Perspective
Current Pharmaceutical Design The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Current Alzheimer Research